As on Wednesday, Keros Therapeutics Inc (NASDAQ: KROS) got off with the flyer as it spiked 6.18% to $66.45, before settling in for the price of $62.58 at the close. Taking a more long-term approach, KROS posted a 52-week range of $27.31-$73.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -40.00%. Meanwhile, its Annual Earning per share during the time was -111.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 3.31%. This publicly-traded company’s shares outstanding now amounts to $31.84 million, simultaneously with a float of $29.84 million. The organization now has a market capitalization sitting at $2.49 billion. At the time of writing, stock’s 50-day Moving Average stood at $57.30, while the 200-day Moving Average is $55.16.
Keros Therapeutics Inc (KROS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Keros Therapeutics Inc’s current insider ownership accounts for 20.47%, in contrast to 81.21% institutional ownership. According to the most recent insider trade that took place on Aug 13 ’24, this organization’s Director sold 250,000 shares at the rate of 44.01, making the entire transaction reach 11,002,500 in total value, affecting insider ownership by 119,522. Preceding that transaction, on Aug 13 ’24, Company’s Director sold 250,000 for 44.01, making the whole transaction’s value amount to 11,002,500. This particular insider is now the holder of 119,522 in total.
Keros Therapeutics Inc (KROS) Earnings and Revenue Records
Keros Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 3.31% and is forecasted to reach -5.42 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 4.80% through the next 5 years, which can be compared against the -111.11% growth it accomplished over the previous five years trading on the market.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Let’s observe the current performance indicators for Keros Therapeutics Inc (KROS). It’s Quick Ratio in the last reported quarter now stands at 20.37. The Stock has managed to achieve an average true range (ATR) of 2.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9234.59.
In the same vein, KROS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.13, a figure that is expected to reach -1.26 in the next quarter, and analysts are predicting that it will be -5.42 at the market close of one year from today.
Technical Analysis of Keros Therapeutics Inc (KROS)
Through scrutinizing the latest numbers posted by the [Keros Therapeutics Inc, KROS], it can be observed that its last 5-days Average volume of 0.43 million was better the volume of 0.37 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 78.27% While, its Average True Range was 2.59.
Raw Stochastic average of Keros Therapeutics Inc (KROS) in the period of the previous 100 days is set at 97.93%, which indicates a major rise in contrast to 94.29% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 40.13% that was lower than 47.13% volatility it exhibited in the past 100-days period.
